SEARCH
Biocon on Q3 earnings performance
CNBC-TV18
2019-01-25
Views
152
Description
Share / Embed
Download This Video
Report
Biosimilars business is a very capital intensive and investment intensive in terms of R&D and we will need to raise capital either through private equity or IPO, said Kiran Mazumdar Shaw, Chairperson & MD, Biocon.
Show more
Share This Video
facebook
google
twitter
linkedin
email
Video Link
Embed Video
<iframe width="600" height="350" src="https://vntv.net//embed/x719u0i" frameborder="0" allowfullscreen></iframe>
Preview Player
Download
Report form
Reason
Your Email address
Submit
RELATED VIDEOS
01:00
Biocon Q3 earnings: Expect a strong performance
11:44
Earnings Edge | Syngene's Jonathan Hunt On Q3 Performance | NDTV Profit
02:07
Samsung Electronics shows better performance than expected, Q3 earnings up 17% q/q, down 56% y/y
03:01
Reliance Q3 Results Breaking | Mukesh Ambani | Reliance Q3 Earnings |Q3 With CNBC Awaaz | RJio Shares
13:54
Q2 Review: After Weak Q2, Can Biocon Bounce Back In Q3? | BQPrime
06:31
Biocon Q3 meets estimates, business grew by 23%
01:48
Biocon Q1 earnings today: Here’s what to expect
04:41
Biocon Q3 net profit at Rs 105 cr vs Rs 92 cr, up 14%
02:48
Roblox Q3 Earnings Highlights: Shares Are Trading Higher After The Company Reported Q3 Financial Results
00:00
Biocon and HealthCare Global In Focus | Earnings Edge | NDTV Profit
18:51
Q3 Review | Nucleus Software's Q3 Earnings See Sharp Uptick; Can It Continue?
01:52
Ulta Beauty Q3 Earnings Highlights: Shares Are Trading Higher After The Company Reported Better-Than-Expected Q3 Sales Results And Revised FY23 Guidance